FibroBiologics Raises $3M via 2.27M Share Offering and Warrants
FibroBiologics closed a best efforts public offering of 2,272,728 shares and warrants at $1.32 each, raising gross proceeds of approximately $3 million. The warrants, exercisable after stockholder approval at an exercise price of $1.32, could yield an additional $3 million if fully exercised.
1. Offering Details
FibroBiologics completed a best efforts public offering of 2,272,728 shares of common stock and accompanying warrants at a combined price of $1.32 per share or equivalent. The aggregate gross proceeds were approximately $3 million before deducting placement agent fees and offering expenses.
2. Warrant Terms and Potential Proceeds
Each warrant carries an exercise price of $1.32 per share and becomes exercisable upon stockholder approval of the warrant share issuance. If fully exercised on a cash basis, the warrants could provide FibroBiologics with an additional $3 million over their five-year term.
3. Use of Proceeds
FibroBiologics intends to allocate net proceeds from the offering toward working capital and general corporate purposes, supporting ongoing research and development efforts across its clinical-stage pipeline of fibroblast-based therapies.